Alnylam Pharmaceuticals (ALNY) Fundamental Analysis: Revenue, Earnings & Valuation

1.53 / 10

Underperform

Fundamental rating is Underperform with a 1.5/10 quality score. Strengths include solid Days Sales Outstanding and Accounts Receivable turnover, but weak points are high Income‑Tax‑to‑Profit ratio and poor PB‑ROE. Overall, the company shows defensive characteristics and limited growth potential.

Analysis Checks(7/10)

Total operating revenue (YoY growth rate %)

Value65.19

Score2/3

Weight0.50%

1M Return0.07%

Days sales outstanding

Value57.33

Score2/3

Weight0.86%

1M Return0.11%

Accounts receivable turnover ratio

Value6.28

Score2/3

Weight-8.21%

1M Return-1.17%

Profit-MV

Value-1.08

Score2/3

Weight54.81%

1M Return6.32%

PB-ROE

Value9.35

Score0/3

Weight24.11%

1M Return2.91%

Income tax / Total profit (%)

Value2.91

Score1/3

Weight-7.37%

1M Return-1.02%

Interest coverage ratio (EBIT / Interest expense) (%)

Value3.29

Score2/3

Weight-8.89%

1M Return-1.25%

Operating revenue (YoY growth rate %)

Value65.19

Score2/3

Weight0.46%

1M Return0.06%

Cost of sales ratio (%)

Value18.36

Score3/3

Weight9.60%

1M Return1.16%

Asset-MV

Value-0.55

Score0/3

Weight34.15%

1M Return4.19%

Is ALNY fundamentally strong?

ALNY scores 1.53/10 on fundamentals and holds a Premium valuation at present. Backed by its 73.28% ROE, 8.45% net margin, 130.21 P/E ratio, 51.77 P/B ratio, and 209.63% earnings growth, these metrics solidify its Underperform investment rating.